{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ALIMTA&page=10", "query": { "intervention": "ALIMTA", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 626, "total_pages": 63, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ALIMTA&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ALIMTA&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T10:12:44.254Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00216216", "title": "Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2005-01", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2011-05-02", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 16, "location_summary": "Newark, Delaware • Galesburg, Illinois • Elkhart, Indiana + 11 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Elkhart", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00216216" }, { "nct_id": "NCT00520936", "title": "A Study of Pemetrexed in Children With Recurrent Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteosarcoma", "Medulloblastoma", "Sarcoma, Ewing's", "Neuroblastoma (Measurable Disease)", "Neuroblastoma (Metaiodobenzylguanidine", "Positive Evaluable)", "Rhabdomyosarcoma", "Ependymoma", "Non-brainstem High-grade Glioma" ], "interventions": [ { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 72, "start_date": "2007-09", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2011-02-25", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520936" }, { "nct_id": "NCT02409342", "title": "A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 572, "start_date": "2015-07-20", "completion_date": "2022-03-08", "has_results": true, "last_update_posted_date": "2023-03-15", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 9, "location_summary": "La Jolla, California • New Haven, Connecticut • Boca Raton, Florida + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02409342" }, { "nct_id": "NCT05715229", "title": "Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2023-09-29", "completion_date": "2026-08-13", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05715229" }, { "nct_id": "NCT03955042", "title": "Pemetrexed for the Treatment of Chordoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chordoma" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Saint John's Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-09-06", "completion_date": "2023-01-18", "has_results": false, "last_update_posted_date": "2023-03-07", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03955042" }, { "nct_id": "NCT00254319", "title": "Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Untreated Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Avastin, Alimta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cooper Health System", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-11-16", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 1, "location_summary": "Voorhees Township, New Jersey", "locations": [ { "city": "Voorhees Township", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00254319" }, { "nct_id": "NCT05410145", "title": "A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS P.G12C" ], "interventions": [ { "name": "D3S-001", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "D3 Bio (Wuxi) Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 442, "start_date": "2022-08-03", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Denver, Colorado + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05410145" }, { "nct_id": "NCT04993677", "title": "A Study of SEA-CD40 Given With Other Drugs in Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Carcinoma, Non-Small- Cell Lung" ], "interventions": [ { "name": "SEA-CD40", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2021-10-06", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 23, "location_summary": "Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04993677" }, { "nct_id": "NCT06452277", "title": "A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Non-small Cell Lung Cancer, HER2 Mutation" ], "interventions": [ { "name": "Sevabertinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2024-08-28", "completion_date": "2029-06-27", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 25, "location_summary": "Newport Beach, California • San Diego, California • San Francisco, California + 20 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06452277" }, { "nct_id": "NCT03819465", "title": "A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "MEDI5752", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "AZD2936", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 175, "start_date": "2018-12-27", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-23T10:12:44.254Z", "location_count": 3, "location_summary": "Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819465" } ] }